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This article reviews selected important mechanistic simi-
larities and differences in alcoholic steatohepatitis, nonal-
coholic steatohepatitis, and toxicant-associated
steatohepatitis.
Hepatic steatosis and steatohepatitis are common histo-
logic ﬁndings that can be caused by multiple etiologies. The
three most frequent causes for steatosis/steatohepatitis
are alcohol (alcoholic steatohepatitis, ASH), obesity/
metabolic syndrome (nonalcoholic steatohepatitis, NASH),
and environmental toxicants (toxicant-associated steato-
hepatitis, TASH). Hepatic steatosis is an early occurrence
in all three forms of liver disease, and they often share
common pathways to disease progression/severity. Dis-
ease progression is a result of both direct effects on the
liver as well as indirect alterations in other organs/tissues
such as intestine, adipose tissue, and the immune system.
Although the three liver diseases (ASH, NASH, and TASH)
share many common pathogenic mechanisms, they also
exhibit distinct differences. Both shared and divergent
mechanisms can be potential therapeutic targets. This re-
view provides an overview of selected important mecha-
nistic similarities and differences in ASH, NASH, and TASH.
(Cell Mol Gastroenterol Hepatol 2015;1:356–367; http://
dx.doi.org/10.1016/j.jcmgh.2015.05.006)
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http://dx.doi.org/10.1016/j.jcmgh.2015.05.006Hhistologic ﬁndings that can be caused by multiple
etiologies (Figure 1). The three most frequent causes for
steatosis/steatohepatitis are alcohol, obesity/metabolic
syndrome, and environmental toxicants, as reviewed herein.
Alcohol remains one of the most common causes of both
acute and chronic liver disease in the United States.1 In
Western countries, up to 50% of cases of end-stage liver
disease have alcohol as a major etiologic factor.2 Excessive
alcohol consumption is the third leading preventable cause
of death in the United States. Alcohol-related deaths,
excluding accidents/homicides, accounted for 22,073 deaths
in the United States in 2006, with 13,000 of those specif-
ically attributed to alcoholic liver disease (ALD).3 Cirrhosisfrom any cause represents the 12th leading cause of death
in the United States, and 45.9% of all cirrhosis deaths are
attributed to alcohol.4 As shown by early studies involving
controlled drinking with subsequent liver biopsies in vol-
unteers, almost everyone who drinks heavily for 12 weeks
will develop fatty liver.5,6 This usually resolves with absti-
nence, but a subset of people who continue to drink heavily
will develop alcoholic hepatitis, which may progress to
cirrhosis or even hepatocellular carcinoma (HCC).
The progression of ALD is somewhat similar to nonal-
coholic fatty liver disease (NAFLD) and toxicant-associated
fatty liver disease (TAFLD) in that it generally occurs over
several years. Importantly, studies from the Veterans
Administration (VA) have shown that patients with cirrhosis
and superimposed alcoholic hepatitis had >60% mortality
over a 4-year period, with most of those deaths occurring in
the ﬁrst few months.7 Thus, the prognosis for this aggres-
sive stage of ALD is worse than for many common types of
cancer, such as breast, prostate, and colon.
We have known that hepatic steatosis is associated with
obesity since at least the 1950s. However, it was not until
1980, when Ludwig et al8 coined the term “nonalcoholic
steatohepatitis—NASH” to describe this previously un-
named condition that often occurred in cirrhotic patients,
that its clinical importance became recognized. NAFLD en-
compasses a pathologic spectrum of liver disease that
ranges from steatosis to steatohepatitis, cirrhosis, and he-
patocellular carcinoma. NAFLD is by far the most common
Figure 1. Multiple etio-
logic factors and meta-
bolic pathways lead to
the same histologic liver
abnormalities.
July 2015 Mechanisms of ASH, NASH, and TASH 357cause of liver disease and abnormal enzymes in children and
adults in the United States, with about one-third of adults
thought to have NAFLD. The U.S. unselected prevalence of
NASH is estimated to be 2% to 5%. Dietary factors,
including high-fat and high-fructose diets, have been asso-
ciated with the development of NASH.
Over 60 million unique chemicals were registered with
the Chemical Abstracts Service Registry as of May 2011.
With the rapid pace of new chemical discovery and
commercialization, it is impossible to fully deﬁne the po-
tential impact of these substances on the liver. However, the
problem appears signiﬁcant: 33% of the 677 most common
workplace chemicals reported in the National Institute of
Occupational Safety and Health Pocket Guide are associated
with hepatotoxicity.9 We ﬁrst coined the term toxicant-
associated steatohepatitis (TASH) in 2010, related to a
cohort of patients with high vinyl chloride exposure who
had classic steatohepatitis on liver biopsy but were not
obese and did not drink alcohol.10 Many classes of industrial
chemicals have been associated with steatosis or steatohe-
patitis. These include (but are not limited to): solvents and
other halogenated hydrocarbons, volatile organic mixtures,
persistent organic pollutants, pesticides, and some nitro-
organic compounds.11 Recently enacted federal legislation
(the Janey Ensminger Act of 2012) mandates medical
coverage through the Department of Veteran’s Affairs for
hepatic steatosis in military personnel who were exposed to
solvents in the drinking water at Marine Corps Base Camp
Lejeune.12 In addition to exposure level, an individual’s
susceptibility to chemical-induced liver disease is deter-
mined by polymorphisms in the genes of xenobiotic meta-
bolism, concomitant use of alcohol or prescription
medications, nutritional factors, and obesity—as many
organic chemicals are lipid soluble.This article reviews the mechanisms for the develop-
ment of steatohepatitis, highlighting mechanistic differences
as well as many common pathways between the three major
etiologies (Table 1). For example, alcohol and the environ-
mental toxicant vinyl chloride are both metabolized through
cytochrome P450 2E1 (CYP2E1) to form toxic aldehyde
intermediates. Moreover, fructose is also metabolized to an
aldehyde. Thus, three divergent forms of steatohepatitis can
have an aldehyde as an intermediate. On the other hand,
dietary unsaturated fat may play a protective role in NASH,
but n-6 unsaturated fat appears to augment ALD. There can
also be major interactions between types of steatohepatitis.
For example, high-fat feeding and subsequent NASH mark-
edly reduces glutathione S-transferases, which play a pro-
tective role against a variety of environmental toxicants and
alcohol. This review evaluates selected mechanistic simi-
larities and differences in alcoholic steatohepatitis (ASH),
NASH, and TASH.Mechanisms of Liver Disease
Nutritional Abnormalities
Moderate/severe alcoholic hepatitis is usually associ-
ated with malnutrition. In large VA cooperative studies,
virtually every patient with alcoholic hepatitis had some
degree of malnutrition.13 Almost 50% of patients’ energy
intake came from alcohol. Although their calorie intake
was frequently adequate, their intake of protein and crit-
ical micronutrients was often deﬁcient. A classic example
of micronutrient deﬁciency is zinc deﬁciency.14,15 Alco-
holics regularly have decreased dietary intake of zinc as
well as poor absorption and increased excretion. More-
over, oxidative stress causes zinc to be released from





















































ALT, alanine aminotransferase; ASH, alcoholic steatohepatitis; AST, aspartate transaminase; BMI, body mass index; LPS,
lipopolysaccharide; NASH, nonalcoholic steatohepatitis; TASH, toxicant-associated steatohepatitis.
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injury, altered fat metabolism, and impaired liver regen-
eration as well as produce classic clinical manifestations of
zinc deﬁciency in humans such as night blindness or skin
lesions.
In the VA cooperative studies, the severity of liver dis-
ease correlated with malnutrition. Patients were given a
balanced 2500-kcal hospital diet which was carefully
monitored by a dietitian. Voluntary oral food intake corre-
lated in a stepwise fashion with 6-month mortality data.
Thus, patients who voluntarily consumed more than 3000
kcal/day had virtually no mortality, whereas those
consuming less than 1000 kcal/day had greater than 80%
6-month mortality. Thus, global malnutrition and speciﬁc
micronutrient depletion (eg, zinc) appear to play a role in
alcoholic hepatitis.
The type of dietary fat consumed also appears to play an
important role in the pathogenesis of ALD. Several studies
have shown that dietary saturated fat protects against
alcohol-induced liver disease in rodents, whereas dietary
unsaturated fat enriched in linoleic acid (LA) promotes
alcohol-induced liver damage.16 The mechanism(s) by
which the combination of LA and alcohol promotes liver
injury are not fully understood. LA is the most abundant
polyunsaturated fatty acid in human diets and in human
plasma and membrane lipids. Dietary intake of LA has more
than tripled over the past century. LA can be enzymatically
converted to bioactive oxidation products—oxidized LA
metabolites (OXLAMs)—primarily via the actions of 12/15-
lipoxygenase or nonenzymatically via free-radical-mediated
oxidation response to oxidative stress. OXLAMs (either
alone or in conjunction with ethanol) can induce increased
gut permeability and hepatic mitochondrial dysfunction inexperimental ALD. OXLAMs are also postulated to play an
etiologic role in NASH.
In contrast to ASH, NASH is commonly associated with
overnutrition and obesity. This is especially true in the United
States. However, it is important to note that in most well-
performed studies, especially pediatric studies, the amount
of total calories consumed is similar in obese patients with or
without NAFLD/NASH. Thus, total caloric intake does not
seem to be the discriminating factor in the development of
fatty liver. Individual dietary components have been postu-
lated to play a role. High-carbohydrate diets, especially those
high in sugared drinks including fructose, have been impli-
cated.17 Moreover, endogenous production of fructose from
high glucose intake has also been implicated in experimental
NAFLD.18 Similarly, high-fat diets likely play a role in NAFLD.
However, diets high in saturated fats have generally been
implicated in NAFLD (compared to unsaturated fats with
ASH). These saturated fats are thought to cause hepatic lip-
otoxicity. Moreover, certain fatty acids may activate Toll-like
receptors and induce inﬂammation/injury. There is
increased visceral adiposity in human and experimental
NAFLD, and the adipocytes are enlarged and inﬂamed. On the
other hand, adipocytes from ALD patients are actually
smaller than normal but still inﬂamed.
Although the vinyl chloride-exposed patients originally
described with TASHwere not overweight,10 other chemicals
are obesogens that disrupt endocrine signaling to cause
steatosis.19,20 Likewise, chemicals may modify the hepatic
response to diet-induced obesity and mediate the transition
from steatosis to steatohepatitis. This has recently been
demonstrated for important food contaminants including
polychlorinated biphenyls,21 arsenic,22 perﬂuorooctanoic
acid,23 and water disinfection byproducts.24,25 High-fat diet
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tion,22–25 oxidative stress,23–26 ﬁbrosis,22,24 and aryl hydro-
carbon receptor and/or nuclear receptor signaling,21,23,27
Not only may ethanol worsen TASH,28 solvents may also in-
crease ethanol drinking behavior.29,30 Thus, nutritional
status modulates environmental liver disease, and environ-
mental chemicals, in turn, inﬂuence the development and
severity of both ALD and NAFLD. Dietary supplementation
with oligofructose has been shown to improve steatohepa-
titis associated with arsenic and high-fat diet coexposures,31
indicating a potential therapeutic role for nutrition in TASH.Intestinal Barrier Dysfunction/Microbiota
Alcohol, and speciﬁcally acetaldehyde, disrupts tight
junction proteins and increases gut permeability both
in vitro and in vivo; increased endotoxin levels are regularly
observed in rodent models of ALD. Elevated endotoxin
levels in ALD may originate from 1) Gram-negative bacterial
overgrowth in the intestine, 2) increased intestinal perme-
ability, and/or 3) impaired hepatic clearance of endotoxin.32
Endotoxin then stimulates the production of tumor necrosis
factor (TNF) and other proinﬂammatory cytokines through
Toll-like receptor 4 (TLR4) signaling, which plays a critical
role in the development and progression of ALD (Figure 2).
Other bacteria-derived toxins, such as peptidoglycan and
ﬂagellin, may also impact TLR signaling and proin-
ﬂammatory cytokine production.32 Indeed, injectedFigure 2. Alteration in gut-barrier function can lead to
translocation of gut-derived products/toxins, which
translocate and activate Toll-like receptors with subse-
quent production of inﬂammatory mediators, liver injury,
and low-grade systemic inﬂammation.peptidoglycan increases liver injury/inﬂammation in
alcohol-fed compared with control-fed mice, and ethanol
feeding increases peptidoglycan levels.32,33 Moreover,
chronic alcohol feeding increases hepatic TLRs and thus
sensitizes hepatocytes to inﬂammation/injury induced by
translocation of gut-derived bacteria/toxins. Endotoxin not
only plays a role in the fatty liver and liver injury of
experimental ALD, but it also appears to play a role in he-
patic ﬁbrosis. In vitro assays as well as in vivo mixed
chimerism studies show that endotoxin primes stellate cells
for transforming growth factor–stimulated collagen pro-
duction.34 Thus, lipopolysaccharide (LPS) also plays a role
in ﬁbrosis induction and progression.
Alterations in the gut microbiome likely play a major role
in the development/progression of gut barrier dysfunction,
endotoxemia, and liver injury/ﬁbrosis of ALD.35 We have
shown that ethanol consumption can cause a time-
dependent decline in the abundance of both Bacteriodetes
and Firmicutes, which was accompanied by a proportional
increase in Actinobacteria and Proteobacteria;36 notably, the
latter phylum encompasses pathogenic Gram-negative spe-
cies such as Escherichia, Salmonella, Vibrio, and Helicobacter.
These results strongly suggest that the increase in plasma
endotoxin levels and hepatic inﬂammation are conse-
quences of the expansion of the Gram-negative bacteria
from the Proteobacteria phylum, which occurs in response
to chronic ethanol consumption. Importantly, gut micro-
biome changes are important in the pathogenesis of human
ALD (as well as human NAFLD/TAFLD), and probiotic
therapy has improved liver enzymes in clinical trials in
human ASH/NASH.37–39
The stability of the normal intestinal microbiome is
inﬂuenced by several factors in the luminal environment,
including gastric acidity, gut motility, bile salts, immunologic
defense factors, colonic pH, and the competition between
microorganisms for nutrients and intestinal binding sites.
An altered luminal environment may lead to modiﬁcations
in the microbial composition by supporting the growth of
speciﬁc genera. Thus, a major increase of Alcaligenes (an
alkaline-tolerant genus) correlates with an increase in fecal
pH and a decrease in fecal short-chain fatty acids. Further,
some short-chain fatty acids (eg, butyrate) have important
signaling functions and epigenetic consequences, and they
are a critical energy source for the intestine.40 Increased
luminal pH, leading to pathogenic alterations, has been
implicated in diverse disease states ranging from infantile
diarrhea to liver cirrhosis.
Substantial data from experimental animal studies sup-
port the concept that the role of gut bacteria in NAFLD/
NASH is multifactorial and includes regulation of energy
homeostasis,41 modulation of choline42 and bile acid meta-
bolism,43 and/or the ability to generate bacteria-derived
toxins such as LPS.44 Small intestine bacterial overgrowth
has also been linked to NASH pathogenesis.45 Elevated
representation of Escherichia, alcohol-producing bacteria,
was observed in parallel with increased blood alcohol con-
centration in NASH patients, suggesting a novel mechanism
for the pathogenesis of NASH: gut microbiota enriched in
alcohol-producing bacteria (eg, E. coli) constantly produce
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role in the disruption of intestinal tight junctions, hepatic
oxidative stress, and liver inﬂammation.46
The gut bacteria may facilitate progression from the
simple steatosis to NASH. Dysbiosis associated with the loss
of NLRP3 (NOD-like receptor family, pyrin domain-
containing 3), and NLRP6 inﬂammasomes resulted in
increased inﬂux of LPS and bacterial DNA to the liver; these
bacterial products stimulate TLR4 and TLR9, respectively,
leading to enhanced hepatic TNFa expression which drives
NASH progression.47 The gut microbiota may also
contribute to hepatic ﬁbrosis via stimulation of TLR9-
dependent proﬁbrotic pathways in hepatic Kupffer cells.48
An exciting advance in the ﬁeld has been the recent obser-
vation that gut microbiota transplantation from donor mice
with NAFLD replicated the phenotype in wild-type re-
cipients, demonstrating that NAFLD is a potentially trans-
missible process.49
Environmental toxicants can also alter the gut micro-
biome and its metabolic activity. Exposure to the environ-
mental toxicant arsenic affects large populations both
worldwide and in the United States, especially through
contamination of drinking water. Recent studies by Lu
et al50 showed that arsenic exposure produces major al-
terations in the gut microbiome, and arsenic-treated mice
were clearly delineated from control mice on metabolic
proﬁles by principal component analysis. Moreover,
clear-cut interactions between the high-fat diet and arsenic-
induced steatohepatitis as well as altered fecal metabolites/
microbiome have also been reported.22,31,51 Likewise,
polychlorinated biphenyl exposures have been associated
with both intestinal dysbiosis52 and increased gut
permeability.53Immune Alterations and Inﬂammatory Mediators
The immune system, including both innate—mediated
by neutrophils, macrophages, natural killer (NK) and natural
killer T (NKT) cells—and adaptive—mediated by T and B
cells—immune responses, is an important pathogenic
component of fatty liver diseases.54 Macrophages and liver
Kupffer cells are major producers of proinﬂammatory and
anti-inﬂammatory cytokines (eg, TNFa, interleukin 8 [IL-8],
and IL-10) and play a critical role, particularly in early fatty
liver disease.55 Moreover, Kupffer cells can activate the
adaptive immune cells (T cells) and hepatic stellate cells
(HSCs) via IL-6 and transforming growth factor-b. Kupffer
cell depletion was shown to reduce hepatic damage and
inﬂammation in alcohol-induced56 and choline-deﬁcient
diet-induced steatohepatitis.57
Neutrophils are an initial inﬂammatory response to
injury, and their inﬁltration into the liver in response to
chemoattractant cytokines is a pathologic hallmark of fatty
liver and most prominently ALD.58,59 The contribution of
neutrophils in NASH development is also becoming evident
in mouse models60,61 and human NASH,62 with the occur-
rence of both apoptosis and necrosis shown in humans.63
Hepatic inﬂammation along with steatosis and hepato-
toxicity is observed in TAFLD, but the data are scarce. Dioxin(2,3,7,8-tetrachlorodibenzo-p-dioxin [TCDD]) administration
in immature, ovariectomized C57B/l/6 mice either alone or
in combination with another environmental pollutant,
PCB153 (2,20,4,40,5,50-hexachlorobiphenyl), resulted in he-
patic histologic changes that included lipid accumulation and
inﬂammatory cell inﬁltration.64 Subchronic exposure of mice
to the pesticide malathion for 28 days resulted in hepatic
steatosis and inﬂammation with neutrophil activation.65
Further studies after exposures to various toxins will better
establish the role of immune alterations in TAFLD.
The adaptive immune system is considered important in
fatty liver, particularly in the advanced stages with a more
progressive phenotype and signiﬁcant ﬁbrosis. Alcoholic
hepatitis patients have an increased number of T cells in the
liver and increased circulating antibodies against lipid per-
oxidation adducts, suggesting that adaptive immune acti-
vation may contribute to the ALD pathogenesis.66–69
Adaptive immune responses also contribute to hepatic
inﬂammation in NAFLD.70
Studies in humans and animals suggest that NKT cells
may be signiﬁcant contributors to inﬂammation, cell death,
and ﬁbrosis in NAFLD.69,71,72 Moreover, evidence demon-
strates a signiﬁcant decrease of CD4þ regulatory T cells in a
high fat diet mouse model of fatty liver.73,74 Recently,
another subset of helper T cells, TH17 cells, that secrete IL-
17 and induce inﬂammation via neutrophils has been
identiﬁed and is thought to play a role in fatty liver. TH17
responses are involved in human ALD75 and may be
important for progression from simple steatosis to steato-
hepatitis in NAFLD.76 Gadd et al77 recently reported that in
all stages of NAFLD the portal tracts were enriched by
CD68þ macrophages and CD8þ lymphocytes. Further,
Miyagi et al78 demonstrated a protective role of invariant
NKT cells in the progression from inﬂammation to ﬁbrosis,
without alteration of steatosis, in a high-fat mouse model.
Cross-talk between various immune cells as well as in-
teractions with other liver cells may also be critical de-
terminants in fatty liver.79 T cells are important activators of
HSCs; while activated, HSCs can act as antigen-presenting
cells to stimulate T cells (including NKT cells and CD4þ
and CD8þ T cells).80 Some studies have suggested that
regulatory T cells may promote oncogenesis and tumor
progression leading to HCC because they mediate immu-
nosuppressive effects and inhibit NK and CD8þ T cells.81 In
addition, hepatocytes are major producers of immunomod-
ulatory cytokines such as IL-8,82 and they are targets for
cytokine toxicity. Thus, many liver cells and peripheral
inﬁltrating immune cells are involved inﬂammation and
damage in fatty liver.
Fat-derived products (such as acrolein, leukotrienes, and
OXLAMs), and advanced glycation end products can also
cause liver inﬂammation and injury.83,84 Factors that acti-
vate the inﬂammasome, such as uric acid, can induce pro-
duction of IL-1 and IL-18. The release of damage-associated
molecular patterns from dying cells, is also believed to
trigger sterile inﬂammation following tissue injury.85 All
these inﬂammatory/ﬁbrotic mediators have been shown to
be increased in fatty liver and are potential targets for
therapeutic intervention.
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Oxidative stress is an imbalance between pro-oxidants
and antioxidants. Reactive oxygen species and reactive ni-
trogen species (RNS) are products of normal metabolism
and can be beneﬁcial to the host (eg, by contributing to
bacterial killing).86 Overproduction of reactive oxygen spe-
cies and RNS, inadequate antioxidant defenses (eg, low
levels of vitamins, selenium, or mitochondrial glutathione),
or both can lead to liver injury. Oxidative stress in ASH,
NASH, or TASH is usually documented by detection of one of
several indirect markers: 1) protein oxidation (eg, protein
thiol or carbonyl products), 2) lipid oxidation (eg, iso-
prostanes or malondialdehyde), 3) DNA oxidation (eg, oxo-
deoxyguanosine), or 4) depletion or induction of antioxidant
defenses (eg, vitamin E, glutathione, or thioredoxin).87
The stimulus for oxidative stress in the liver comes from
multiple sources. In hepatocytes, CYP2E1 activity increases
after alcohol consumption—in part because of stabilization
of messenger RNA (mRNA). Similarly, CYP2E1 activity is
increased in NAFLD. The CYP2E1 system leaks electrons to
initiate oxidative stress.86 CYP2E1 is localized in the hepatic
lobule in areas of alcohol-induced liver injury. Moreover,
overexpression of CYP2E1 in mice and in HepG2 cells (a
human hepatoma cell line) in vitro leads to enhanced
alcohol hepatotoxicity. Nonparenchymal cells and inﬁl-
trating inﬂammatory cells (eg, polymorphonuclear neutro-
phils) are another major source of pro-oxidants that are
used for normal cellular processes such as killing invading
organisms. Inﬁltrating neutrophils use enzyme systems such
as myeloperoxidase to generate hypochlorous acid (HClO,
a halide species that causes oxidative stress) and RNS.
Hepatic steatosis in TAFLD caused by exposure to
methyl mercury is associated with increased lipid peroxi-
dation products in rat livers.88 Inhibition of pyruvate de-
hydrogenase in the mitochondria, with resultant
mitochondrial uncoupling and an increase in hydrogen
peroxide production,89 has been shown with elevated free
radicals and lipid peroxidation products in multiple studies
of arsenic-induced TAFLD.90 Carbon tetrachloride is another
well-studied hepatotoxicant that induces hepatic steatosis
and injury after cleavage of CCl4 by CYP2E1, which gener-
ates the trichloromethyl radical and leads to lipid peroxi-
dation and membrane damage.91 We recently demonstrated
that PCB153 exposure causes TASH with hepatic antioxidant
depletion.26
Oxidative stress can mediate liver injury through at least
two major pathways: direct cell injury and cell signaling.
Direct cell injury is indicated by markers such as lipid
peroxidation and DNA damage. An even greater role is
played by signaling pathways; for example, activation of
transcription factors such as nuclear factor kB plays a crit-
ical role in the production of proinﬂammatory cytokines
such as TNF.
Of all the mechanisms related to ASH, NASH, and TASH,
oxidative stress has probably been the most widely studied.
Antioxidant therapy offers potential as a clinical interven-
tion for steatohepatitis. Importantly, there is no therapy
approved by the U.S. Food and Drug Administration for anyform of steatohepatitis. Moreover, vitamin E therapy (800 IU
per day) is possibly the only widely accepted therapy for
any form of steatohepatitis (in this case, NASH; see
Table 1).92 Unfortunately, therapy is beyond the scope of
this article, but each of the listed mechanisms for steato-
hepatitis represents a potential therapeutic target.
Endoplasmic Reticulum Stress
Endoplasmic reticulum (ER) stress, or the unfolded
protein response pathway, is activated by conditions of
protein overload or increased unfolded proteins. Once
triggered, this signaling pathway results in adaptation and
recovery of homeostasis; however, severe or prolonged ER
stress can ultimately result in cell death.
Increasing evidence has demonstrates that ER stress is a
common feature of many liver diseases, including ASH and
NASH.93,94 Alcohol-induced ER stress is seen in experi-
mental alcohol-feeding models in mice, micropigs, rats, and
zebraﬁsh.95–98 ER stress has been also been reported in
human patients with ALD,99,100 with up-regulation of mul-
tiple ER stress markers, which correlated with dysregulated
lipid metabolism and impaired insulin signaling. This sug-
gests that ER stress is integral to ALD pathogenesis in hu-
man alcoholics. The induction of hepatic ER stress has been
described in several genetic and diet-induced murine
models of obesity, insulin resistance, and NAFLD, and in the
livers of patients with NAFLD.101–104
Some upstream mechanisms that are demonstrated to
cause ER stress in NAFLD include 1) hepatic steatosis/excess
fatty acids, 2) oxidative stress and deﬁcient nuclear factor
erythroid 2-related factor 2 (Nrf2), 3) impaired hepatic
autophagy in NAFLD patients and murine models of NAFLD,
and 4) down-regulation of adiponectin.105–107 Several
alcohol-induced factors are also known to cause ER stress in
ASH, including acetaldehyde and toxic lipid-derived alde-
hydes and metabolites, oxidative stress, dysregulated
methionine metabolism, aberrant epigenetic modiﬁcations,
altered interferon regulatory factor 3 (IRF3)/Sting signaling,
and disruption of calcium homeostasis.108,109
Overall, hepatic ER stress occurs in both ASH and NASH
in many species including humans, and is now accepted as
an important mechanism in disease pathogenesis and pro-
gression. However, because ER stress appears to be both a
cause and a consequence of other accompanying alterations,
the question of association versus causality remains. The
association of ER stress and TAFLD is highly likely but less
well investigated. Thus, the exact role of ER stress in the
pathogenesis of ALD, NAFLD, and TAFLD warrants further
investigation to facilitate the development of therapies.Fibrin/Extracellular Matrix
Fibrosis results from an imbalance between production
and resorption of extracellular matrix (ECM) caused by a
complex interplay between activation/transdifferentiation
of HSCs, proﬁbrogenic growth factors and cytokines, and
alterations in the ﬁbrin coagulation system. Fibrosis and the
altered ECM subsequently provide a permissive setting for
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dominant contributors to ﬁbrosis in the liver driven by
varied etiology, and upon activation they produce proﬁ-
brogenic factors such as collagen and smooth muscle
actin.110 Although a mechanistic link between apoptosis or
necroptosis and HSC activation has been suggested, it is not
fully understood.
Hepatic injury in experimental models of liver disease
often involves dysregulation of the ﬁbrin cascade, resulting
in the formation of ﬁbrin clots that can cause hepatocellular
death and induce inﬂammatory signaling in the liver. Inhi-
bition of ﬁbrinolysis by plasminogen activator inhibitor-1
(PAI-1) can cause ﬁbrin-ECM to accumulate, even in the
absence of enhanced ﬁbrin deposition by the thrombin
cascade. An imbalance in coagulation factors as well as
elevated PAI-1 levels and hypoﬁbrinolysis are common in
patients with either NAFLD or ALD.111 Indeed, it has been
shown that circulating plasma PAI-1 levels in humans are
closely related to the degree of liver steatosis.112 Coagula-
tion cascade activation has also been shown to be critical for
liver inﬂammation and steatosis in Western-diet-induced
NAFLD, and PAI-1 levels during disease development are a
predictor of later severity.113 Fibrosis is also commonly
seen in TAFLD caused by exposure to drugs114 and vinyl
chloride.10 Also, exposure of mice to the dioxin TCDD results
in hepatic steatosis and ﬁbrosis with up-regulation of pro-
ﬁbrogenic genes.115 However, the underlying mechanisms
remain undetermined.Genetics/Epigenetics
Recent studies have shown that both genetic and
epigenetic factors are important for disease pathogenesis
and progression in steatohepatitis. The genetic variations
are often associated with conformational changes in protein
structures and functions due to single-nucleotide poly-
morphisms (SNPs), whereas epigenetic changes are pheno-
typic changes resulting from altered gene expression
without affecting the underlying DNA sequence.
Genomewide association studies have identiﬁed around
3.1 million SNPs that can contribute to disease states, and
these SNPs may increase or decrease the function of enco-
ded proteins. Speciﬁcally, a study conducted by Romeo
et al116 showed 9229 SNPs in NAFLD patients as compared
with controls. Some of the more important ones appeared to
be patatin-like phospholipase domain-containing 3 (PNP
LA3), peroxisome proliferator-activated receptor-g (PPAR-g),
and TNFa.117 In NAFLD, TNFa-238, adiponectin-45,
leptin 2548 PPAR-g-161, and phosphatidylethanolamine
N-methyltransferase-175 (PEMT-175) have an increased
risk association, and adiponectin-276 and hepatic lipase-
514 have a negative or decreased risk association.118 In
ALD, polymorphisms of alcohol metabolizing enzymes such
as alcohol dehydrogenase and CYP2E1 as well as antioxi-
dant enzymes and cytokine-coding genes have shown a
strong correlation with the progression of ALD.119
Epigenetic changes occurring in response to various
environmental signals can produce diverse tissue-speciﬁc
effects. These epigenetic modiﬁcations include microRNAs(miR), DNA methylation, and histone modiﬁcations. The role
of microRNA is well established in both NASH and ASH.
Some of these microRNAs play a causal role, as they have
targets that are important for the development of disease,
but others likely are seen only as associations. A decrease in
miR-122 and induction in miR-155 expression has been
reported in models of NASH and ASH. Mice deﬁcient in
miR-122 develop steatohepatitis and ﬁbrosis. TNF and CEBP
are the targets of miR-155. Additionally, other microRNAs
such as miR-320, miR-486, miR-705, miR-1224, miR-27b,
miR-214, miR-199a, miR-192, and miR-183 likely
contribute to both diseases.120 Importantly, there is a strong
association between HCC, which can arise from ALD, NAFLD,
or TAFLD, and hepatic microRNA alterations.121,122
The potential role of alcohol induced histone modiﬁca-
tions in the development of ALD has been observed in several
in vivo and in vitro studies. Increases in histone H3 acetyla-
tion have been documented resulting from increased histone
acetyltransferase activity and histone deacetylase (HDAC)
inhibition. Reduced expression of sirtuin 1 (SIRT 1), a class III
HDAC, has been shown in alcohol-exposed hepatocytes and is
known to regulate the lipid metabolism pathway. Our own
studies support this notion. We have shown that dysregula-
tion of hepatic HDAC expression plays a major role in the
binge alcohol-induced hepatic steatosis and liver injury by
affecting lipogenesis and fatty acid b-oxidation.123 In DNA
methylation studies, hypermethylation has been observed in
PPARGC1A (PPAR-g coactivator 1a) and TFAM (mitochon-
drial transcription factor A) promoters in NAFLD livers. In
ALD, decreased S-adenosyl-L-methionine levels seem to in-
ﬂuence DNA methylation. Decreased S-adenosyl-L-methio-
nine is known to induce global hypomethylation and regional
hypermethylation of various promoters, and such changes
are hypothesized to contribute to ASH.
Our analysis of environmental chemicals associated with
TAFLD showed that exposures to chemicals that cause he-
patic steatosis also can lead to multigenerational toxic ef-
fects in offspring, strongly suggesting that epigenetic
alterations may be responsible.124 Long-term exposure of
humans to high concentrations of arsenic is hepatotoxic and
associated with an increased risk of cancer. Arsenic-induced
fatty liver and hepatotoxicity are closely associated with
both DNA damage (genetic changes) and DNA methylation
(epigenetic changes), and such alterations may lead to the
development of liver cancer.125 Interestingly, long-term
arsenic exposure has been shown to down-regulate p16
(INK4a) by targeting recruitment of G9a and H3K9 dime-
thylation without changing DNA methylation in the normal
mouse liver, and these changes occurred in the absence of
tumorigenesis, suggesting that they may be precursors.126Cell Death
Deﬁning mechanisms for hepatocyte cell death is a crit-
ical area of interest for liver injury of all etiologies, and the
common modes of cell death relevant to this article are
apoptosis, necrosis, and necroptosis.127 Apoptotic death has
been demonstrated in ALD and NAFLD in both animal
models and humans; moreover, apoptosis and necrosis
July 2015 Mechanisms of ASH, NASH, and TASH 363frequently coexist in liver pathology. We have observed
coexistent apoptosis and necrosis in human ASH and NASH,
with necrosis tending to be more dominant in ASH and
apoptosis in NASH. Our work has shown that hepatocyte
necrosis (rather than apoptosis) is seen in TASH;128 this is
also a primary death mechanism with other hepatotoxins
such as carbon tetrachloride. Acetaminophen-induced liver
injury evokes both necrosis and necroptosis.129,130 Inter-
estingly, unlike ALD and NAFLD, which are typically asso-
ciated with elevated aspartate transaminase (AST) and
alanine aminotransferase (ALT) activities, TAFLD is
commonly associated with normal liver enzymes.10 Alco-
holic liver disease classically has AST>ALT whereas NAFLD
usually has ALT predominance. These liver enzyme proﬁles
are sometimes helpful in identifying/suggesting an under-
lying cause of liver injury (eg, alcohol abuse in someone who
does not provide a reliable alcohol history, NAFLD in a
nonobese patient). Dying hepatocytes, particularly during
necrosis/necroptosis, can release pathogenic mediators or
damage-associated molecular patterns such as lipid-derived
metabolites (eg, aldehydes), HMGB1 (high-mobility group
box 1), formyl peptides, and mitochondrial DNA, which
trigger inﬂammation and cell death in neighboring hepato-
cytes and exacerbate liver damage.Conclusions
Fatty liver disease (ASH, NASH, TASH) occurs as a result
of varied etiologies (see Figure 1) and can progress to his-
tologically identical, more severe liver disease. Disease
progression is a result of both direct effects on the liver as
well as indirect alterations in other organs/tissues such as
intestine, adipose tissue, and the immune system. Although
the three diseases share many common pathogenic mecha-
nisms, they also exhibit distinct differences. Both shared and
divergent mechanisms can be potential therapeutic targets.
Better biomarkers for ASH, NASH, and TASH and improved
model systems that more closely resemble human disease
will promote future mechanistic investigations and thera-
peutic development.
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